May 5, 2007 

 

The number of clinical trial drugs increased significantly in January and march 

 

In the first quarter of 2017, the number of drugs declared for clinical trials in the country was 238, according to the mienet clinical trial. Overall, the number of clinical trials in February was slightly lower than in January. The number of clinical trials for stage I, IV clinical and bioequivalence was the most significant in March. 

 

Figure 1: the number of registered clinical trials in China in the first quarter of the first quarter of this year 

 

 

The classification of clinical medicines in the first quarter 

 

According to the classification of drugs, the chemical drugs accounted for 76.47%, and biological products accounted for 21.43 percent, and Chinese medicine/natural medicines accounted for only 2.10 percent. 

 

Is worth to pay close attention to the following varieties: in chemical medicine than listed on the world's first BTIK inhibitor with higher selectivity of ibrutinib paekche shenzhou BGB - 3111 in January, has entered a phase II clinical trials. In addition, jiangsu hengrui PD - 1 single resistance injection with SHR - 1210 also carried out in January indications for phase II clinical trials of non-small cell lung cancer, the variety has been in April in phase III clinical. 

 

Biological medicine single biological resistance method is worthy of attention in zhuhai, which is used in the independent research and development of rheumatoid arthritis, psoriasis, autoimmune diseases such as ankylosing spondylitis class 1 injection drug use recombinant humanized anti-tumor necrosis factor alpha monoclonal antibody in March has entered a phase II clinical trials. 

 

FIG. 2:17 in the first quarter of the first quarter of the year 

 

 

Clinical trials of antitumor drugs were the highest in the first quarter 

 

Currently, antitumor drugs are one of the important areas of the pharmaceutical market and one of the biggest areas of research and development of pharmaceutical production enterprises. In the first quarter of 2017, anti-tumor and immune-regulating agents were ranked first in clinical trials in China. Antitumor and immunologic agents accounted for 16.90 per cent and 25.35 per cent of the antitumor drugs. 

 

Figure 3: the categories of the anti-tumor and immune-regulating agents 

 

 

Medicine for his drugs, hangzhou eisen domestic first to the third generation of EGFR inhibitors ivey, conducted in March for phase I clinical indications for non-hodgkin's lymphoma. In February, a clinical trial of the use of toluene sulfonate capsules in the guangdong eastern sun was conducted in February with the indications of IIIB or IV non-small cell lung cancer. 

 

The current high-profile new type of tumor therapy, pd-1 / pd-l1, has been a focus of research and development since its introduction. In the first quarter of the first quarter, there were some advances in the drugs of pd-l1 immunotherapy. In this case, the drug's Atezolizumab injection was developed in February with a phase III clinical trial of urothelial and small-cell lung cancer. Astrazeneca's MEDI4736 was developed in January and February in phase III clinical trials for non-small-cell lung cancer and urothelial carcinoma. The Pembrolizumab injection in msantoon, which was developed in January, was a phase III clinical trial for gastric cancer, and in March, the indications were phase III clinical for non-small cell lung cancer and hepatocellular carcinoma. 

 

In the first quarter of the trial, the body was ranked second third with a total of 13.45 per cent and 10.92 per cent of the digestive and digestive systems. Of the digestive and metabolic drugs, 57.69% were treated for diabetes. 

 

FIG. 4:17 in the first quarter of the first quarter of the year the domestic clinical trial drug treatment category situation 

 

 

Fourth, the first quarter carries on the medicine clinical trial main hospital circumstance 

 

There were 99 clinical trials in the first quarter of 2017, with 12 out of five. 

 

In the hospital for clinical trials, jilin university first hospital topped the list with 19 drugs. The clinical drugs of the first hospital in jilin university are mainly concentrated in the field of anti-infective drugs and anti-tumor and immune-regulating agents, with 8 and 4 drugs respectively. 

 

The Chinese academy of medical sciences' tumor hospital was followed by 11 clinical trials. As the national standardization tumor diagnosis and treatment quality control center and the national cancer clinical medical research center, the hospital for clinical trials of drugs are the anti-tumor and immune modulators. 

 

Table 1: the main hospital for clinical trials of drugs in the first quarter of 1717 

 

 

In the first quarter, the first five companies were in clinical trials 

 

In the first quarter of 2017, the top five companies for clinical trials are domestic enterprises, which shows the strong r&d potential of domestic enterprises. 

 

Zhengda to 13 clinical drug number at the top of the list, the weather is fine, TQ - B3101 capsule, TQ - B3234 capsule and hydrochloric acid for ernesto capsule 1.1 class new medicine for the state, the three are the anti-tumor and immune modulators. It is worth noting that the maleic acid horse Chinese fir Joan is the first approved for the treatment of multiple recurrent or refractory invasive B cell non-hodgkin's lymphoma patients group of drugs, the ongoing clinical trials of an enterprise only a zhengda shine. 

 

Jiangsu hengrui followed with nine clinical trials, including three new drugs. It is worth noting that hengrui class 1 new drug injection in SHR - 1210 in January in the indications for phase II clinical trials of non-small cell lung cancer has the variety in April in phase III clinical, is the first domestic into phase III clinical PD - 1 single drug resistance. 

 

The third group, qilu pharmaceuticals, has a 1.1 class new drug in phase II clinical trials. Toluene sulfonic acid Sarah for piece for molecular targeted anti-tumor drugs, in September 2012 by the former state and drug administration (SFDA) allowed into phase I clinical trial of examination and approval, in January 2017 in phase II clinical. 

 

Haizheng was ranked fourth among six clinical trials, among them, haizema and the injected peg-sn38, a new type of new drug. Haizema is the 1.1 class of new cholesterol-lowering drugs developed by the Marine industry. An injection of peg-sn38, which is used in the treatment of breast cancer, colorectal cancer and pediatric tumors, was used in the phase I clinic in February. 

 

Of the five drugs in the quarterly clinical trial in hausen, jiangsu province, 1.1 new drugs took up four seats. The hs-10220 capsules and the hs-10234 are the digestive and metabolic drugs and the whole body with anti-infective drugs. The hs-10241 and fluorazole are both anti-tumor and immune-regulating agents. Among them, hs-10241 was a c-met inhibitor, a new anti-tumor drug in hausen, jiangsu province, which entered stage I in March. 

 

In the first quarter of the first quarter of the year, the number of clinical trial drugs was in the top five